AR and Familial prostate cancer: A number of phosphoserine-specific antibodies have been described for the AR [3,16–18] and the availability of these antibodies provides the possibility of screening clinical samples for changes in receptor phosphorylation, which is of utmost importance for a fuller understanding of the role of this chemical modification in prostate cancer disease progression and may be utilized to predict response to abiraterone.